Skip to main content
Erschienen in: Tumor Biology 5/2013

01.10.2013 | Research Article

Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk

verfasst von: Guofeng Zhang, Yu Zeng, Zhongyan Liu, Weiwei Wei

Erschienen in: Tumor Biology | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Many studies were published to evaluate the association between Nijmegen breakage syndrome 1 (NBS1) 657del5 polymorphism and breast cancer risk, but the results remained inconsistent. To derive a more precise estimation on the possible association, we performed a meta-analysis of previous published studies. Case–control studies on the association between NBS1 657del5 polymorphisms and breast cancer risk were included into this meta-analysis. We used the odds ratio (OR) with 95 % confidence interval (95 % CI) to assess the strength of the association. Ten studies with a total of 25,365 subjects were identified and included into this meta-analysis. Meta-analysis of those ten studies showed that there was a significant association between NBS1 657del5 polymorphisms and breast cancer risk (pooled OR = 2.66, 95 % CI 1.82–3.90, P < 0.001). The cumulative meta-analyses showed a trend of a more significant association between NBS1 657del5 polymorphisms and breast cancer risk as data accumulated by publication year. Thus, our meta-analysis suggests that there was a significant association between NBS1 657del5 polymorphisms and breast cancer risk, and NBS1 657del5 polymorphism results in an increased risk of breast cancer.
Literatur
1.
Zurück zum Zitat Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12:496–503.CrossRefPubMed Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12:496–503.CrossRefPubMed
2.
Zurück zum Zitat Higgins MJ, Baselga J. Breast cancer in 2010: novel targets and therapies for a personalized approach. Nat Rev Clin Oncol. 2011;8:65–6.CrossRefPubMed Higgins MJ, Baselga J. Breast cancer in 2010: novel targets and therapies for a personalized approach. Nat Rev Clin Oncol. 2011;8:65–6.CrossRefPubMed
3.
Zurück zum Zitat Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.CrossRefPubMed Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.CrossRefPubMed
4.
Zurück zum Zitat Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378:1812–23.CrossRefPubMed Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378:1812–23.CrossRefPubMed
5.
Zurück zum Zitat Tauchi H, Matsuura S, Kobayashi J, Sakamoto S, Komatsu K. Nijmegen breakage syndrome gene, NBS1, and molecular links to factors for genome stability. Oncogene. 2002;21:8967–80.CrossRefPubMed Tauchi H, Matsuura S, Kobayashi J, Sakamoto S, Komatsu K. Nijmegen breakage syndrome gene, NBS1, and molecular links to factors for genome stability. Oncogene. 2002;21:8967–80.CrossRefPubMed
6.
Zurück zum Zitat Huang J, Grotzer MA, Watanabe T, Hewer E, Pietsch T, Rutkowski S, et al. Mutations in the Nijmegen breakage syndrome gene in medulloblastomas. Clin Cancer Res. 2008;14:4053–8.CrossRefPubMed Huang J, Grotzer MA, Watanabe T, Hewer E, Pietsch T, Rutkowski S, et al. Mutations in the Nijmegen breakage syndrome gene in medulloblastomas. Clin Cancer Res. 2008;14:4053–8.CrossRefPubMed
7.
Zurück zum Zitat Maser RS, Zinkel R, Petrini JH. An alternative mode of translation permits production of a variant NBS1 protein from the common Nijmegen breakage syndrome allele. Nat Genet. 2001;27:417–21.CrossRefPubMed Maser RS, Zinkel R, Petrini JH. An alternative mode of translation permits production of a variant NBS1 protein from the common Nijmegen breakage syndrome allele. Nat Genet. 2001;27:417–21.CrossRefPubMed
8.
Zurück zum Zitat Carlomagno F, Chang-Claude J, Dunning AM, Ponder BA. Determination of the frequency of the common 657del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer. Genes Chromosomes Cancer. 1999;25:393–5.CrossRefPubMed Carlomagno F, Chang-Claude J, Dunning AM, Ponder BA. Determination of the frequency of the common 657del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer. Genes Chromosomes Cancer. 1999;25:393–5.CrossRefPubMed
9.
Zurück zum Zitat Gorski B, Debniak T, Masojc B, Mierzejewski M, Medrek K, Cybulski C, et al. Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer. 2003;106:379–81.CrossRefPubMed Gorski B, Debniak T, Masojc B, Mierzejewski M, Medrek K, Cybulski C, et al. Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer. 2003;106:379–81.CrossRefPubMed
10.
Zurück zum Zitat Buslov KG, Iyevleva AG, Chekmariova EV, Suspitsin EN, Togo AV, Kuligina E, et al. NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia. Int J Cancer. 2005;114:585–9.CrossRefPubMed Buslov KG, Iyevleva AG, Chekmariova EV, Suspitsin EN, Togo AV, Kuligina E, et al. NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia. Int J Cancer. 2005;114:585–9.CrossRefPubMed
11.
Zurück zum Zitat Gorski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, et al. Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat. 2005;92:19–24.CrossRefPubMed Gorski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, et al. Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat. 2005;92:19–24.CrossRefPubMed
12.
Zurück zum Zitat Kanka C, Brozek I, Skalska B, Siemiatkowska A, Limon J. Germline NBS1 mutations in families with aggregation of breast and/or ovarian cancer from north-east Poland. Anticancer Res. 2007;27:3015–8.PubMed Kanka C, Brozek I, Skalska B, Siemiatkowska A, Limon J. Germline NBS1 mutations in families with aggregation of breast and/or ovarian cancer from north-east Poland. Anticancer Res. 2007;27:3015–8.PubMed
13.
Zurück zum Zitat Roznowski K, Januszkiewicz-Lewandowska D, Mosor M, Pernak M, Litwiniuk M, Nowak J. I171V germline mutation in the NBS1 gene significantly increases risk of breast cancer. Breast Cancer Res Treat. 2008;110:343–8.CrossRefPubMed Roznowski K, Januszkiewicz-Lewandowska D, Mosor M, Pernak M, Litwiniuk M, Nowak J. I171V germline mutation in the NBS1 gene significantly increases risk of breast cancer. Breast Cancer Res Treat. 2008;110:343–8.CrossRefPubMed
14.
Zurück zum Zitat Mateju M, Kleiblova P, Kleibl Z, Janatova M, Soukupova J, Ticha I, et al. Germline mutations 657del5 and 643C>T (R215W) in NBN are not likely to be associated with increased risk of breast cancer in Czech women. Breast Cancer Res Treat. 2012;133:809–11.CrossRefPubMed Mateju M, Kleiblova P, Kleibl Z, Janatova M, Soukupova J, Ticha I, et al. Germline mutations 657del5 and 643C>T (R215W) in NBN are not likely to be associated with increased risk of breast cancer in Czech women. Breast Cancer Res Treat. 2012;133:809–11.CrossRefPubMed
15.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
16.
Zurück zum Zitat Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term “cost effective” in medicine. N Engl J Med. 1986;314:253–6.CrossRefPubMed Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term “cost effective” in medicine. N Engl J Med. 1986;314:253–6.CrossRefPubMed
17.
Zurück zum Zitat Zintzaras E, Lau J. Synthesis of genetic association studies for pertinent gene–disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol. 2008;61:634–45.CrossRefPubMed Zintzaras E, Lau J. Synthesis of genetic association studies for pertinent gene–disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol. 2008;61:634–45.CrossRefPubMed
18.
Zurück zum Zitat Muellerleile P, Mullen B. Sufficiency and stability of evidence for public health interventions using cumulative meta-analysis. Am J Public Health. 2006;96:515–22.PubMedCentralCrossRefPubMed Muellerleile P, Mullen B. Sufficiency and stability of evidence for public health interventions using cumulative meta-analysis. Am J Public Health. 2006;96:515–22.PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Steffen J, Varon R, Mosor M, Maneva G, Maurer M, Stumm M, et al. Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int J Cancer. 2004;111:67–71.CrossRefPubMed Steffen J, Varon R, Mosor M, Maneva G, Maurer M, Stumm M, et al. Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int J Cancer. 2004;111:67–71.CrossRefPubMed
21.
Zurück zum Zitat Steffen J, Nowakowska D, Niwinska A, Czapczak D, Kluska A, Piatkowska M, et al. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer. 2006;119:472–5.CrossRefPubMed Steffen J, Nowakowska D, Niwinska A, Czapczak D, Kluska A, Piatkowska M, et al. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer. 2006;119:472–5.CrossRefPubMed
22.
Zurück zum Zitat Bogdanova N, Feshchenko S, Schurmann P, Waltes R, Wieland B, Hillemanns P, et al. Nijmegen breakage syndrome mutations and risk of breast cancer. Int J Cancer. 2008;122:802–6.CrossRefPubMed Bogdanova N, Feshchenko S, Schurmann P, Waltes R, Wieland B, Hillemanns P, et al. Nijmegen breakage syndrome mutations and risk of breast cancer. Int J Cancer. 2008;122:802–6.CrossRefPubMed
23.
Zurück zum Zitat Zhang Y, Zhou J, Lim CU. The role of NBS1 in DNA double strand break repair, telomere stability, and cell cycle checkpoint control. Cell Res. 2006;16:45–54.CrossRefPubMed Zhang Y, Zhou J, Lim CU. The role of NBS1 in DNA double strand break repair, telomere stability, and cell cycle checkpoint control. Cell Res. 2006;16:45–54.CrossRefPubMed
24.
Zurück zum Zitat Thompson LH. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat Res. 2012;751:158–246.CrossRefPubMed Thompson LH. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat Res. 2012;751:158–246.CrossRefPubMed
25.
Zurück zum Zitat Kondratenko I, Paschenko O, Polyakov A, Bologov A. Nijmegen breakage syndrome. Adv Exp Med Biol. 2007;601:61–7.CrossRefPubMed Kondratenko I, Paschenko O, Polyakov A, Bologov A. Nijmegen breakage syndrome. Adv Exp Med Biol. 2007;601:61–7.CrossRefPubMed
26.
Zurück zum Zitat van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011;34:71–88.CrossRef van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011;34:71–88.CrossRef
27.
Zurück zum Zitat Dodson GE, Limbo O, Nieto D, Russell P. Phosphorylation-regulated binding of CTP1 to NBS1 is critical for repair of DNA double-strand breaks. Cell Cycle. 2010;9:1516–22.PubMedCentralCrossRefPubMed Dodson GE, Limbo O, Nieto D, Russell P. Phosphorylation-regulated binding of CTP1 to NBS1 is critical for repair of DNA double-strand breaks. Cell Cycle. 2010;9:1516–22.PubMedCentralCrossRefPubMed
Metadaten
Titel
Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk
verfasst von
Guofeng Zhang
Yu Zeng
Zhongyan Liu
Weiwei Wei
Publikationsdatum
01.10.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0830-z

Weitere Artikel der Ausgabe 5/2013

Tumor Biology 5/2013 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.